Current targeted therapies in the treatment of advanced colorectal cancer: a review

Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone dramatic changes in the past decade and despite improved patient outcomes, there still exist areas for continued development. The introduction of targeted agents has provided clinicians with additional treatment options in mCRC, however, results have been mixed at best. These novel therapies were designed to interfere with specific molecules involved in the cellular carcinogenesis pathway and ultimately deliver a more focused treatment. Currently, their use in mCRC has been limited primarily as an adjunct to conventional chemotherapy regimens. This review explores the relevant cell-signaling networks in colorectal cancer, provides focus on the current targeted agent armamentarium approved for use in mCRC and explores the usefulness of predictive mCRC biomarkers.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/295PFLU
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Current targeted therapies in the treatment of advanced colorectal cancer: a review

CYP17 inhibitors in prostate cancer: latest evidence and clinical potential

Since androgen signaling plays a pivotal role in the proliferation and metastasis of prostate cancer, androgen deprivation therapy (ADT) or castration therapy is considered the backbone of treatment for newly diagnosed metastatic prostate cancer. However, almost all men experience disease progression on ADT to a state known as metastatic castration-resistant prostate cancer (mCRPC), which continues to be driven by intratumoral androgen synthesis or androgen receptor signaling. Hence, the extragonadal ablation of androgen synthesis from pregnane precursors holds much promise. An inhibitor of cytochrome P450 17α–hydroxy/17,20-lyase (CYP17) enzymes, abiraterone acetate, has already been approved for men with mCRPC. Newer CYP17 inhibitors continue to be developed which are either more selective or have concomitant inhibitory actions on AR signaling. These include VT-464, orteronel, and galeterone. Herein, we focus on the molecular mechanism of action, efficacy, latest evidence, and clinical potential of CYP17 inhibitors in prostate cancer.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/29eRzO7
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

CYP17 inhibitors in prostate cancer: latest evidence and clinical potential

Investigating the therapeutic role and molecular biology of curcumin as a treatment for glioblastoma

Objectives:

Despite the aggressive standard of care for patients with glioblastoma multiforme, survival rates typically do not exceed 2 years. Therefore, current research is focusing on discovering new therapeutics or rediscovering older medications that may increase the overall survival of patients with glioblastoma. Curcumin, a component of the Indian natural spice, turmeric, also known for its antioxidant and anti-inflammatory properties, has been found to be an effective inhibitor of proliferation and inducer of apoptosis in many cancers. The goal of this study was to investigate the expanded utility of curcumin as an antiglioma agent.

Methods:

Using the PubMed MeSH database, we conducted a systematic review of the literature to include pertinent studies on the growth inhibitory effects of curcumin on glioblastoma cell lines based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results:

A total of 19 in vitro and five in vivo studies were analyzed. All of the studies indicated that curcumin decreased glioblastoma cell viability through various pathways (i.e. decrease in prosurvival proteins such as nuclear factor B, activator protein 1, and phosphoinositide 3 kinase, and upregulation of apoptotic pathways like p21, p53, and executor caspase 3). Curcumin treatment also increased animal survival compared with control groups.

Conclusions:

Curcumin inhibits proliferation and induces apoptosis in certain subpopulations of glioblastoma tumors, and its ability to target multiple signaling pathways involved in cell death makes it an attractive therapeutic agent. As such, it should be considered as a potent anticancer treatment. Further experiments are warranted to elucidate the use of a bioavailable form of curcumin in clinical trials.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/295PWyh
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Investigating the therapeutic role and molecular biology of curcumin as a treatment for glioblastoma

Highlighting Welsh cancer research – learn more about our free event here: https://t.co/r3bcTyZsNg

Highlighting Welsh cancer research – learn more about our free event here: https://t.co/r3bcTyZsNg

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://twitter.com/ecancer/status/748581939855134724
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Highlighting Welsh cancer research – learn more about our free event here: https://t.co/r3bcTyZsNg

Dr Vineis explains the systems perspectives of the exposome https://t.co/KvJG1d43IU https://t.co/zMc31ygd71

Dr Vineis explains the systems perspectives of the exposome https://t.co/KvJG1d43IU https://t.co/zMc31ygd71

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://twitter.com/ecancer/status/748569446286036994
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Dr Vineis explains the systems perspectives of the exposome https://t.co/KvJG1d43IU https://t.co/zMc31ygd71